HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Today's Posts

Reply
 
Thread Tools Display Modes
Old 10-30-2009, 02:54 PM   #1
bejuce
Senior Member
 
bejuce's Avatar
 
Join Date: May 2009
Posts: 510
Interesting Research on Breast Cancer Genomes - Different Subtypes identified

I attended the following seminar at UCSF this past Monday:

Genomic and Transcriptomic Landscapes of 1,000 Breast Cancers Carlos Caldas, MD, Professor of Cancer Medicine, University of Cambridge, Senior Group Leader, Cancer Research UK Cambridge Research Institute

“We have now completed the analysis of 1000 breast cancer genomes using high-resolution SNP arrays, gene expression arrays and focused mutation analysis (including TP53). The pathology of the tumors was rigorously assessed and information on histological type, grade, size, lymph node metastasis and ER was available for all cases. This study reveals the molecular taxonomy of breast cancer is more complex than gleaned until now. A copy-number based classification of breast cancer shows there are new subtypes that have been previously missed. Copy number vs. gene expression correlation has highlighted both copy-number dependent as well as copy-number independent chromosomal loci. New breast cancer oncogenes and tumor suppressor genes have been identified. The genomic landscape of breast cancer is therefore extremely complex and this has both biological and clinical implications.


The talk was pretty scientific, but I got some interesting takeaways out of it:


1. There are many breast cancer and tumor suppressor genes that are being researched and yet to be identified in full;
2. It is evident from their research that some DCIS are very genomically unstable while others are not (thereby explaining how some on these board have DCIS that goes on to stage IV quickly, while others do not);
3. There appears to be a distinct class/subtype within the ER+ tumors;
4. Loss of cromosome 16 are more common in grade-1 tumors (not sure exactly the impact of this);
5. Amplification of MYC-PVT1 gene is more common in ER+ tumors;

6. There is a class of ER- tumors with an inflammatory component with very good prognosis; and
7. MYC overexpression is oncogenic and aggressive.


I'll be posting research abstracts from time to time as part of a new advocacy role that I'm taking on (more on that later, my kids want me to play now).

Wishing you all a Happy Halloween!
__________________
ER+ (30%)/PR-/HER-2+, stage 3

Diagnosed on 02/18/09 at 38 with a huge 12x10 cm tumor, after a 6 month delay. Told I was too young and had no risk factors. Found swollen node during breastfeeding.
March-August 09: neo-adjuvant chemo, part of a trial at Stanford (4 DD A/C, 4 Taxotere with daily Tykerb), loading dose of Herceptin
08/12/09 - bye bye boobies (bilateral mastectomy)
08/24/09 - path report shows 100 % success in breast tissue (no cancer there, yay!), 98 % success in lymphatic invasion, and even though 11/13 nodes were still positive, > 95 % of the tumor in them was killed. Hoping for the best!
September-October 09: rads with daily Xeloda
02/25/10 - Cholecystectomy
05/27/10 - Bone scan clear
06/14/10 - CT scan clear, ovarian cyst found
07/27/10 - Done with Herceptin!
02/15/11 - MVA-BN HER-2 vaccine trial
03/15/11 - First CA 15-3: 12.7 and normal, yay!
10/01/11 - Bone scan and CT scan clear, fatty liver found
now on Tamoxifen and Aspirin


bejuce is offline   Reply With Quote
Reply


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 12:06 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter